募资2.7亿！国产医用耗材龙头成功IPO

Core Viewpoint - Aishalon Medical Technology Group Co., Ltd. successfully went public on the Beijing Stock Exchange, marking it as the first new A-share listed company in Jiangsu Province and Suzhou City in 2026, with a focus on stable operational and financial foundations rather than high-risk narratives [1] Company Introduction - Established in 2015 and headquartered in Suzhou, Jiangsu, Aishalon specializes in medical dressings and surgical infection control products, focusing on rehabilitation care and surgical infection control products [5] - The company primarily operates through OEM/ODM models, providing contract manufacturing services for large international medical device companies, with exports to North America, Europe, and South Korea [5] Product and Business Structure - Aishalon's main revenue comes from medical dressing products, particularly care pads, which constitute a significant portion of its overall income [6] - The company has established a comprehensive system covering R&D, production, and quality control, holding ISO 13485 certification and approvals from CE and the US FDA, ensuring stable access to international markets [10] - Aishalon has long-term partnerships with major international medical supply groups like Medline, resulting in stable order flows but also presenting a degree of customer concentration risk [10] Financial Performance - The company has shown steady operational performance, with both revenue and profit experiencing positive growth [11] - Revenue figures indicate a scale of approximately 600-700 million yuan, with continued growth expected post-2024, reflecting strong order and delivery stability [13] - Specific revenue data includes: - 2022: Approximately 573 million yuan - 2023: Approximately 619 million yuan - 2024: Approximately 703 million yuan - 2025 (Jan-Sep): 690 million yuan, a year-on-year increase of 42.84% [15] - Net profit figures are as follows: - 2022: 62.8 million yuan - 2023: 66.9 million yuan - 2024: 80.6 million yuan - 2025 (Jan-Sep): 49.4 million yuan [15][21] - The net profit margin has remained around 11%, indicating a relatively healthy profitability level among medical consumables companies, with profits primarily derived from core operations [16] - As of September 2025, total assets were approximately 1.279 billion yuan, with owner’s equity around 821 million yuan, maintaining a controllable debt ratio and a relatively stable financial structure [17] Industry Observation - Aishalon's listing highlights a path for non-"star innovative device" medical companies to capitalize in a rational capital market environment, providing a clear capitalization model [18] - The continuous entry of such companies into the Beijing Stock Exchange aids in transitioning the medical sector from "single-point innovation" to a coexistence of "multiple types of medical companies" [18] - The emphasis on stable operational capabilities is underscored as a scarce asset within the industry [18]